Edrophonium
From Wikipedia, the free encyclopedia
 |
|
|
Edrophonium
|
|
| Systematic (IUPAC) name | |
| ethyl-(3-hydroxyphenyl)-dimethyl-ammonium | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C10H16NO+ |
| Mol. mass | 166.24 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Edrophonium is a readily reversible acetylcholinesterase inhibitor. It prevents breakdown of the neurotransmitter acetylcholine and acts by inhibiting the enzyme acetylcholinesterase, mainly at the neuromuscular junction. It is sold under the trade names Tensilon®, Enlon® and Reversol®.
[edit] Clinical uses
Because its duration of action is only about 10 minutes, edrophonium is used to differentiate myasthenic crisis from cholinergic crisis. In myasthenic crisis, where a person is not able to produce enough neuromuscular stimulation, edrophonium will reduce the muscle weakness. In a cholinergic crisis, where a person has too much neuromuscular stimulation, edrophonium will make the muscle weakness worse by further calcium in the intracellular space.
[edit] Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
| Anticholinesterases (N06DA, N07AA) edit |
| Metrifonate - Physostigmine - Neostigmine - Pyridostigmine - Ambenonium - Demarcarium - Rivastigmine - Galantamine - Donepezil - Tacrine - Edrophonium |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
